Manorama Industries (541974) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
30 Jun, 2026Executive summary
Achieved strong growth in H1 FY26, driven by value-added products, high plant utilization, and robust demand from global chocolate, confectionery, and cosmetic sectors.
Upgraded annual revenue guidance for FY26 from INR 1,050 crore to INR 1,150 crore+ due to sustained business momentum and operational scalability.
Strategic initiatives include facility upgrades, land acquisition for expansion, and new ventures in West Africa and Latin America to deepen global presence.
Waste-to-wealth sourcing model empowers rural and tribal women, supporting ESG commitments and supply chain reliability.
Reduced working capital days and debt levels, improving capital efficiency and return ratios.
Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.
Financial highlights
H1 FY26 consolidated revenue reached INR 612.9 crore, up 86.4% year-over-year; Q2 FY26 revenue was INR 323.3 crore.
EBITDA for H1 FY26 was INR 156.6 crore (27.2% margin); PAT was INR 105.5 crore (17.2% margin); Q2 FY26 EBITDA INR 87.7 crore (27.1% margin); PAT INR 54.9 crore (17% margin).
H1 FY26 diluted EPS at INR 17.66, up 162% YoY.
Export contribution was 58% of total sales; domestic 42%.
Standalone net profit for Q2 FY26 was ₹5,485.78 lacs; consolidated net profit at ₹5,321.78 lacs.
Outlook and guidance
FY26 revenue guidance revised upward to INR 1,150 crore+.
Confident in sustaining healthy margins and operational efficiency in coming quarters.
Capacity expansion to 52,000 MT per annum expected to drive future growth; full ramp-up could yield INR 1,800-2,000 crore revenue at 100% utilization.
Scheduled plant modification in Q3 FY26 to expand fractionation capacity from 40,000 to 52,000 MTPA.
Further guidance for FY27 and FY28 to be provided in March quarter.
Latest events from Manorama Industries
- Q2 earnings grew as QIP funds supported working capital and expansion plans advanced.541974
Q2 26/27 - Manufacturing growth and capacity investment offset the exit from trading.541974
Q4 18/19 - FY23 growth accelerated as capacity expanded, despite input-cost and execution pressures.541974
Q4 22/23 - Revenue rose 37.8% and PAT 65.6% as expansion targets global specialty-fat demand.541974
Q4 21/22 - FY20 sales rose 84% as a new plant expanded capacity amid pandemic disruption.541974
Q4 19/20 - Revenue advanced, but pandemic pressure cut profit as capacity expansion continued.541974
Q4 20/21 - Q1 FY27 revenue and profit surged, supported by global expansion, capex, and strong margins.541974
Q1 26/27 - Revenue up 76.1%, EBITDA up 92.5%, and major CapEx and expansion plans approved.541974
Q4 25/26 - Record Q3 FY25 revenue and profit, strong margins, and global expansion with new subsidiaries.541974
Q3 24/25